COSTI, Maria Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.835
EU - Europa 15.320
AS - Asia 3.455
SA - Sud America 70
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 26
OC - Oceania 24
Totale 42.767
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.708
GB - Regno Unito 4.585
IT - Italia 4.012
DE - Germania 2.205
SE - Svezia 1.553
CN - Cina 1.350
SG - Singapore 748
FR - Francia 658
UA - Ucraina 601
HK - Hong Kong 495
FI - Finlandia 409
TR - Turchia 353
PL - Polonia 275
BG - Bulgaria 262
IN - India 149
BE - Belgio 144
CA - Canada 122
IE - Irlanda 118
RU - Federazione Russa 101
ID - Indonesia 91
LT - Lituania 72
CH - Svizzera 66
VN - Vietnam 57
NL - Olanda 53
ES - Italia 52
JP - Giappone 49
BR - Brasile 35
IR - Iran 35
MY - Malesia 34
CZ - Repubblica Ceca 33
KR - Corea 32
RO - Romania 23
EU - Europa 21
ZA - Sudafrica 20
PT - Portogallo 19
AU - Australia 17
CL - Cile 15
TW - Taiwan 15
DK - Danimarca 13
AR - Argentina 12
GR - Grecia 10
LU - Lussemburgo 8
PH - Filippine 8
PK - Pakistan 8
MD - Moldavia 7
NZ - Nuova Zelanda 7
AT - Austria 6
HU - Ungheria 6
IL - Israele 6
LI - Liechtenstein 6
RS - Serbia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AE - Emirati Arabi Uniti 5
EG - Egitto 5
JO - Giordania 5
NO - Norvegia 5
EC - Ecuador 4
TZ - Tanzania 4
BD - Bangladesh 3
MX - Messico 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
BY - Bielorussia 2
CO - Colombia 2
DZ - Algeria 2
EE - Estonia 2
IQ - Iraq 2
MA - Marocco 2
MO - Macao, regione amministrativa speciale della Cina 2
AL - Albania 1
BZ - Belize 1
ET - Etiopia 1
GH - Ghana 1
GL - Groenlandia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
NG - Nigeria 1
NP - Nepal 1
SI - Slovenia 1
TN - Tunisia 1
Totale 42.767
Salva come PNG Salva come JPEG
Città #
Southend 3.800
Fairfield 2.982
Houston 2.330
Woodbridge 2.114
Chandler 2.090
Ashburn 1.872
Ann Arbor 1.257
Jacksonville 1.238
Frankfurt am Main 1.182
Seattle 1.145
Dearborn 1.142
Cambridge 1.112
Wilmington 1.047
Nyköping 1.012
Modena 775
Singapore 510
Hong Kong 476
Beijing 374
New York 335
Princeton 289
San Diego 271
Sofia 261
Kraków 255
Eugene 229
Helsinki 219
Izmir 194
Shanghai 179
Fremont 175
Milan 159
Redwood City 154
Boardman 150
Des Moines 126
Bologna 123
Bremen 123
Brussels 115
Dublin 108
London 98
Rome 91
Jakarta 88
Ottawa 80
Parma 75
Falls Church 67
Grafing 58
Dong Ket 52
Hefei 50
Verona 49
Reggio Emilia 46
Norwalk 45
San Mateo 45
Guangzhou 44
Munich 41
Milwaukee 40
Nanjing 40
Naples 40
Turin 40
Padova 38
Kunming 33
Brno 30
Perugia 30
Napoli 29
Phoenix 28
Jinan 27
Washington 27
Ferrara 26
Paris 26
Piacenza 23
Saint Petersburg 23
Amsterdam 22
Los Angeles 22
Sassuolo 22
Toronto 22
Auburn Hills 21
Formigine 20
Prato 20
Hangzhou 19
Kilburn 19
Torino 19
Leawood 18
Trieste 18
Albinea 17
Zurich 17
Augusta 16
Bari 16
Brescia 16
Florence 16
Berlin 15
Indiana 15
Leuven 15
Misterbianco 15
Philadelphia 15
Siena 15
Mountain View 14
San Gimignano 14
Wuhan 14
Catania 13
Chengdu 13
Decatur 13
Dongguan 13
Madrid 13
Messina 13
Totale 31.902
Salva come PNG Salva come JPEG
Nome #
Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase 1.038
STRUTTURA DEL CRISTALLO DEL COMPLESSO DI TIMIDILATO SINTETASI (TS) CON UN LIGANDO 624
TYDOCK PHARMA s.r.l. Spin Off dell'Università di Modena e Reggio Emilia che ha come fine l'attività di ricerca e sviluppo nel settore delle biotech farmaceutiche. 427
Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase 327
Metodo per la funzionalizzazione sito specifica di molecole proteiche 326
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics 317
Internalization and stability of a thymidylate synthase peptide inhibitor in ovarian cancer cells 296
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase 293
An Improved Synthesis of CENTA, a Chromogenic Substrate for β-Lactamases 291
Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase 280
USO DI INIBITORI DELLA PTERIDINA REDUTTASI PER LA PREVENZIONE E/O IL TRATTAMENTO DI INFEZIONI PARASSITARIE 278
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections 267
Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology 260
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance 255
Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery 254
Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth 252
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform 252
Repurposing of drugs targeting yap-tead functions 249
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs 240
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 240
Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides 238
Current and Future Chemotherapy for Chagas Disease 237
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment 234
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines. 232
Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells. 232
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth 229
Antibacterial agent discovery using thymidylate synthase biolibrary screening 229
Decoding the structural basis for carbapenem hydrolysis by class A β- lactamases: fishing for a pharmacophore 228
Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth 228
2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes 227
Translational repression of thymidylate synthase by targeting its mRNA 227
Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones? 226
pH-Promoted Release of a Novel Anti-Tumour Peptide by “Stealth” Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells 224
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections 222
Crystal Structure of histidine-tagged human thymidylate synthase 218
Permeation through the cell membrane of a boron-based β-lactamase inhibitor. 217
Constrained dansyl derivatives reveal bacterial specificity of highly conserved Thymidylate Synthases A 216
Excited-state intramolecular proton transfer in a bioactive flavonoid provides fluorescence observables for recognizing its engagement with target proteins 216
Crystal Structure of human thymidylate synthase bound to a peptide inhibitor 214
Alanine Mutants of the Interface Residues of Human Thymidylate Synthase Decode Key Features of the Binding Mode of Allosteric Anticancer Peptides 214
2′-Deoxyuridine 5′-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives 212
NUOVE MOLECOLE, PER USO COME AGENTI ANTITUMORALI 211
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds 211
Proteomic Approach to the Detection of the Mechanism of Action of Anticancer Peptides 211
X-ray-crystallography deciphers the activity of broad spectrum boronic acid β-Lactamases inhibitors 210
Spermidine/spermine N1-acetyltranferasemodulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistanthuman ovarian cancer cell lines 209
Structure-Based Selectivity Optimization of Piperidine–Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors 206
Thymidylate synthase inhibition: A structure-based rationale for drug design 205
Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections 205
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity 205
Hotspots in an obligate homodimeric anticancer target. structural and functional effects of interfacial mutations in human thymidylate synthase 204
Structure-based studies on species-specific inhibition of thymidylate synthase 203
Thymidylate synthase structure, function and implication in drug discovery 203
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To InhibitTrypanosoma bruceiPteridine Reductase in Support of Early-Stage Drug Discovery 202
Multiligand approach to the identification of resistant strains overexpressing beta-lactamase 202
“A step further in the discovery of phthalein derivatives as Thymidylate Synthase inhibitors” 202
Proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer 200
Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors 199
Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors 197
Dimer-monomer equilibrium of human thymidylate synthase monitored by fluorescenceresonance energy transfer. 196
Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells 196
Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding. 196
Maxwell A: F1000Prime Recommendation of Evaluation [Neres J et al., ACS Chem Biol 2014]. In F1000Prime, 09 Jan 2015; DOI: 10.3410/f.725248139.793502885. F1000Prime.com/725248139#eval793502885 196
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells 196
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent 195
Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations 194
IN SILICO/IN VITRO APPROACHES FOR THE IDENTIFICATION OF NEW CARBAPENEMASE INHIBITORS 194
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 193
Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus 192
Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-beta-lactamases 192
MITO-group Multicenter italian trials in ovarian cancer and gynecological malignancies Borad of directors-translational research group 190
PTEROATE-PEPTIDE BIOCONJUGATE TARGETING THE FOLATE RECEPTOR IN HUMAN OVARIAN CANCER CELL LINES: TRANSPORT AND MECHANISM OF ACTION. 188
Theoretical study of electronic spectra and photophysics of uracil derivatives. 186
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells 186
Update on antifolate drugs targets 185
Theoretical analysis of the addition of hydroxylamine to uracil and 5-fluorouracil as a model for the Thymidylate synthase reaction 185
Tethering low affinity ligands to the dimeric interface of human thymidylate synthase. 184
The 1,10-phenanthroline ligand enhances the antiproliferative activity of dna-intercalating thiourea-pd(Ii) and-pt(ii) complexes against cisplatin-sensitive and-resistant human ovarian cancer cell lines 184
A condensed thiadiazolo-pyrimidine as a new efficient fluorophore. Theoretical and experimental investigation of the electronic spectra and photophysics 183
Homodimeric Enzymes as Drug Targets 183
Biochemical effects of riluzole on Leishmania parasites 183
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity 183
Allosteric Inhibition of human Thymidylate Synthase. 182
Optimization of N-alkylation in the Synthesis of Methotrexate and Pteridine-based Derivatives Under Microwave-Irradiation 180
Protein-protein interaction inhibitors: case studies on Small Molecules and Natural Compounds. 179
CYCLIZATION REACTIONS OF 1,3-DIBROMOPROPAN-2-OL, 2,3-DIBROMOPROPAN-1-OL AND 1-BROMOMETHYLOXIRANE WITH 6-AMINO-2,3-DIHYDRO-2-THIOXO-4(1H)-PYRIMIDINONE 178
Inhibitor of Ovarian Cancer Cells growth by Virtual Screening: A New Thiazole Derivative Targeting Human Thymidylate Synthase 177
Biochemistry: Anchors away 177
Optimizing Cell Permeation of an Antibiotic Resistance Inhibitor for Improved Efficacy 177
Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine 175
Ligand-Based Virtual Screening and ADME-Tox Guided Approach to Identify Triazolo-quinoxalines as Folate Cycle Inhibitors. 175
QUINOXALINE DERIVATIVES AS ANTITUBERCULOSIS AGENTS 173
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development 173
Naphthalimido Derivatives as Antifolate Thymidylate Synthase Inhibitors 173
ANTICANCER DRUGS 172
ACS Medicinal Chemistry Letters. member of the Editorial Board 171
Structure-Based Optimization of a Non-β-lactam Lead Results in Inhibitors That Do Not Up-Regulate β-Lactamase Expression in Cell Culture 170
A proteomic approach to investigate the mechanism of action of anticancer peptides 169
Structural Comparison of Enterococcus faecalis and Human Thymidylate Synthase Complexes with the Substrate dUMP and Its Analogue FdUMP Provides Hints about Enzyme Conformational Variabilities 169
Aprepitant as anticancer drug 168
Totale 22.669
Salva come PNG Salva come JPEG
Categoria #
all - tutte 169.311
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 169.311
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.714 0 0 346 873 1.102 1.125 1.359 918 743 306 473 469
2020/20217.774 750 311 736 642 848 621 558 770 381 1.171 571 415
2021/20225.532 246 536 330 303 243 554 249 356 626 393 1.058 638
2022/20236.329 759 759 421 608 644 897 190 604 753 103 308 283
2023/20245.689 202 278 326 412 1.996 486 280 492 138 133 387 559
2024/20251.111 602 197 312 0 0 0 0 0 0 0 0 0
Totale 43.461